Wei Peu Zen - Director at Emmaus Life Sciences, Inc.

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Wei Peu Zen since 27 Aug 2025

Reported holdings for Wei Peu Zen in Emmaus Life Sciences, Inc.

Form 4 holding Director

Emmaus Life Sciences, Inc.

Security class
Common stock, $0.001 par value
Shares / value
4,768,817
Estimated value
$238,441
Report date
15 Dec 2023
Price
$0.0500
Ownership
Direct
Form 4 holding Director

Emmaus Life Sciences, Inc.

Security class
Common stock, $0.001 par value
Shares / value
1,270,214
Estimated value
$63,511
Report date
15 Dec 2023
Price
$0.0500
Ownership
By Profit Preview International Group Limited
Form 4 holding Director

Emmaus Life Sciences, Inc.

Security class
Options
Shares / value
100,000
Estimated value
$15,000
Report date
01 Feb 2024
Price
$0.1500
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Emmaus Life Sciences, Inc.

Security class
Convertible Promissory Note dated 2023-01-18
Shares / value
0
Estimated value
Report date
18 Jan 2023
Price
$0.5000
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for Wei Peu Zen in Emmaus Life Sciences, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .